BioSig Technologies, Inc. Stock

Equities

BSGM

US09073N3008

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
1.54 USD -5.52% Intraday chart for BioSig Technologies, Inc. +3.36% -67.58%
Sales 2024 * 1.5M Sales 2025 * - Capitalization 14.38M
Net income 2024 * -13M Net income 2025 * - EV / Sales 2024 * 9.58 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-1.03 x
P/E ratio 2025 *
-
Employees 47
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.52%
1 week+3.36%
Current month+132.98%
1 month+180.82%
3 months-47.62%
6 months-75.21%
Current year-67.58%
More quotes
1 week
1.04
Extreme 1.04
2.44
1 month
0.46
Extreme 0.4555
2.98
Current year
0.26
Extreme 0.2619
4.75
1 year
0.26
Extreme 0.2619
16.50
3 years
0.26
Extreme 0.2619
45.80
5 years
0.26
Extreme 0.2619
124.30
10 years
0.26
Extreme 0.2619
124.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 Feb. 26
Chief Administrative Officer 51 09-02-23
Chief Tech/Sci/R&D Officer 74 09-02-23
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 74 09-02-23
Chief Executive Officer 58 Feb. 26
More insiders
Date Price Change Volume
24-04-18 1.54 -5.52% 417,686
24-04-17 1.63 +7.95% 3,990,783
24-04-16 1.51 +37.27% 3,291,789
24-04-15 1.1 -19.12% 370,014
24-04-12 1.36 -8.72% 945,667

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
BioSig Technologies, Inc. is a medical technology company. The Company is focused on commercializing an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Its product PURE EP System is a non-invasive class II device consisting of a combination of hardware and software designed to provide signal clarity and precision for real-time visualization of intracardiac signals, paving the way for personalized patient care. PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated with signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.54 USD
Average target price
50 USD
Spread / Average Target
+3,146.75%
Consensus